![]() ![]() In Mar 2016, the company inked a collaboration agreement with Roche Holding AG’s RHHBY Genentech to evaluate the safety and efficacy of KTE-C19, in combination with atezolizumab, in patients with refractory, aggressive NHL. Note that Kite has been pursuing strategic collaborations to build its immuno-oncology portfolio. In addition, KTE-C19 is being evaluated in a phase II study (ZUMA-2) in patients with relapsed/refractory mantle cell lymphoma (MCL), in a phase I-II study (ZUMA-3) in adults with relapsed/refractory acute lymphoblastic leukemia (ALL), and in a phase I-II study (ZUMA-4) in pediatric patients with relapsed/refractory ALL.Įarlier this month, the FDA granted Orphan Drug designation to KTE-C19 for five indications – PMBCL, MCL, follicular lymphoma (FL), ALL and chronic lymphocytic leukemia (CLL). All these are types of aggressive non-Hodgkin’s lymphoma (NHL). Kite’s lead pipeline candidate, KTE-C19, is an anti-CD19 CAR-based therapy currently in the pivotal phase of a phase I-II study (ZUMA-1) in patients with refractory diffuse large B cell lymphoma (DLBCL) including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). ![]() Moreover, revenues surged 78% to $5.1 million. Last quarter, the company reported a positive surprise of 26.23%. Kite’s track record has been satisfactory so far, with the company reporting a narrower-than-expected loss in two of the four trailing quarters, with an average positive surprise of 4.80%. Kite reported results for the first quarter 2016 on May 9. KITE to a Zacks Rank #3 (Hold) from a Zacks Rank #4 (Sell) On May 12, Zacks Investment Research upgraded Kite Pharma, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |